Transcatheter aortic valve implantation with the self‐expandable venus A‐Valve and CoreValve devices: Preliminary Experiences in China

Liao, Yanbiao; Zhang, Zhengang; Wei, Xin; Yang, Xu; Zuo, Zhi‐Liang; Li, Yijian; Zheng, Maojun; Feng, Yuan; Chen, Mao

doi:10.1002/ccd.26912

Cited by 47 publications

(47 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first three valves on this list are locally manufactured valves from China and the published short-term and midterm results of these valves have been highly encouraging (8,9). However, there is currently only one valve that is fully commercialized in China.…”

Section: Asian Case Volumementioning

confidence: 99%

Transcatheter aortic valve implantation in Asia

Hon

Tay

2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

The use of transcatheter aortic valve implantation (TAVI) to treat severe symptomatic aortic valve stenosis has increased exponentially in the last decade. This rapid expansion was seen predominantly in Western developed nations and has been fuelled by favorable results reported from a plethora of well-publicized randomized controlled trials, large retrospective series and national registries. Now, TAVI has become the standard of care for inoperable patients and an alternative to open surgery in patients who are at intermediate to high risk for open surgery. Notwithstanding these positive results, Asia has been relatively slow to adopt this technology despite a potentially large patient pool. Unique features of Asian medical environments and differences in Asian anatomy affecting TAVI uptake in Asia will be discussed. This article serves to outline the various challenging aspects of disseminating TAVI in Asian countries.

show abstract

Section: Asian Case Volumementioning

confidence: 99%

Transcatheter aortic valve implantation in Asia

Hon

Tay

2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

show abstract

“…The total cases of TAVR procedures performed in China are less than 800 cases and many heart centers have little or no TAVR experience. Chinese patients undergoing TAVR have a higher calcification burden of the aortic valve and more bicuspid pathology than patients from Europe or North America . Importantly, a TAVR device suited for Chinese patients should be designed with these aforementioned challenges in mind.…”

Section: Introductionmentioning

confidence: 99%

VitaFlow™ transcatheter valve system in the treatment of severe aortic stenosis: One‐year results of a multicenter study

Zhou

Pan

Wang

et al. 2019

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Venus A‐Valve is composed of a self‐expandable multilevel support nitinol frame mounted with three porcine pericardial leaflets at the supra‐annular position, the key features of the device has been described previously . Valve sizing in the present study was primarily based on aortic annulus dimension (perimeter) according to the vendor‐recommended sizing chart, unless there was predictable excessive oversizing relative to supra‐annular structures even after desired reshaping with the TAV8 balloon.…”

Section: Methodsmentioning

confidence: 99%

“…With proven noninferiority or even superiority to surgery among elderly AS patients in different risk categories, TAVR has been increasingly used in younger and lower risk groups. With the anticipated downshifting of patients' age, bicuspid aortic valve (BAV) disease will be an increasingly common condition for TAVR operators, as has already been reflected in the TAVR experience in China, where the mean age of patients undergoing TAVR is roughly 75 years and the incidence of BAV is approximately 50% …”

Section: Introductionmentioning

confidence: 99%

Reshaping bicuspid aortic valve stenosis with an hourglass‐shaped balloon for transcatheter aortic valve replacement: A pilot study

Zhang

Feng

Liao

et al. 2020

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Objectives We evaluated the safety and usefulness of preparatory anatomical reshaping with a geometric hourglass‐shaped balloon to optimize transcatheter aortic valve replacement (TAVR) outcomes in bicuspid aortic valve (BAV) stenosis. Background TAVR has been increasingly performed for BAV stenosis; however, technical challenges remain. Procedural results are suboptimal given unfavorable valvular anatomies. Methods Eligible patients with BAV stenosis were enrolled to undergo aortic valve predilatation with the hourglass‐shaped TAV8 balloon before TAVR using the self‐expandable Venus A‐Valve. Procedural details and outcomes were compared to a sequential group of patients with BAV who underwent TAVR with the same device following preparatory dilatation using a cylindrical balloon. Results A total of 22 patients were enrolled in the TAV8 group and 53 were included in the control group. Valve downsizing was less common in the TAV8 group (36.4 vs. 67.9%; p = .012). Stable valve release and optimal implant depth were consistently achieved in the TAV8 group with no requirement for a second valve (0 vs. 17.0%; p = .039) and with higher device success rates (100.0 vs 77.4%; p = .014). Residual aortic regurgitation graded as ≥mild was less common in the TAV8 group (13.6 vs 45.3%; p = .009). Mortality was similar (0 vs. 3.8%; p = 1); no major/disabling stroke or conversion to open‐heart surgery was seen in either group within 30 days. Conclusions Compared with standard cylindrical balloon valvuloplasty, preparatory reshaping with the hourglass‐shaped balloon before self‐expandable TAVR in BAV was associated with significantly better procedural results and may encourage more promising outcomes.

show abstract

Transcatheter aortic valve implantation with the self‐expandable venus A‐Valve and CoreValve devices: Preliminary Experiences in China

Abstract: TAVI with the domestic Venus A-Valve is feasible, safe, and can produce favorable short-term outcomes comparable to those with the CoreValve in inoperable or high-risk patients with tricuspid and bicuspid aortic valve stenosis. © 2017 Wiley Periodicals, Inc.

Cited by 47 publications

References 27 publications

Transcatheter aortic valve implantation in Asia

Transcatheter aortic valve implantation in Asia

VitaFlow™ transcatheter valve system in the treatment of severe aortic stenosis: One‐year results of a multicenter study

Reshaping bicuspid aortic valve stenosis with an hourglass‐shaped balloon for transcatheter aortic valve replacement: A pilot study

Contact Info

Product

Resources

About